Bozepinib is used as a PKR (RNA-dependent protein kinase) activator; it effectively inhibits the HER-2 signaling pathway as well as JNK and ERK kinases; induces PKR-mediated apoptosis; synergizes with IFNα to trigger apoptosis, autophagy, and senescence; and demonstrates in vivo antitumor and antimetastatic efficacy in xenografted nude mice.